PRIMA Retinal Implant: 2-mm Device Restores Vision

For patients who have lost central vision to advanced geographic atrophy, the problem is not simply that the eye is “out of focus.” The photoreceptors responsible for detailed central vision have been destroyed. 

The PRIMA retinal implant takes a different approach: it does not try to regenerate those cells. It bypasses them. 

The system combines a tiny photovoltaic retinal implant with camera-equipped glasses and an external processor. Visual information captured by the glasses is converted into near-infrared signals and projected onto the implant. The implant converts that light into electrical stimulation, activating surviving retinal neurons. 

The result is not normal sight. It is prosthetic form vision. But the clinical results are significant: in the pivotal study, 26 of 32 patients assessed at 12 months achieved clinically meaningful visual-acuity improvement, while 27 of 32 could read letters, numbers and words using prosthetic vision. 

And as of July 2026, the PRIMA retinal implant has moved another step closer to becoming a real-world medical technology: Science Corporation has received CE marking and launched PRIMA commercially in Europe, with the first commercial implantation expected in Germany. 

The Problem: When Central Vision Is Gone 

The PRIMA retinal implant is designed for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). 

GA progressively destroys the central retina. Patients may retain peripheral vision but lose the high-resolution central vision required for reading, recognizing faces and navigating detailed environments. 

The clinical literature describes GA as affecting more than 5 million people worldwide, while existing therapies have focused on slowing disease progression rather than restoring already-lost central vision. 

That is the gap PRIMA is attempting to fill. 

How Does the PRIMA Retinal Implant Work? 

The PRIMA retinal implant essentially creates a new information pathway into the surviving retina. 

The Signal Pathway 

Camera-equipped glasses capture the visual scene. An external processor converts the information into signals that are projected as near-infrared light onto the implanted photovoltaic array. 

The implant then converts that optical energy into electrical stimulation, activating surviving retinal neurons. 

The important point is that PRIMA is not simply an implanted camera. 

The camera remains outside the eye. 

Instead, the implant functions as an optical-to-electrical neural interface that communicates with surviving retinal circuitry. 

The PRIMA Retinal Implant Is Only 2 × 2 Millimeters 

The scale of the device is one of the most striking aspects of the technology. 

The original PRIMA retinal implant is approximately 2 × 2 mm, with a photovoltaic array containing 378 pixels. The early device used approximately 100-µm pixels and near-infrared illumination. 

PRIMA at a Glance 

This is where the engineering becomes particularly interesting. 

The implant has to be sufficiently small to sit beneath the retina, yet its pixels must generate enough electrical stimulation to activate surviving retinal neurons. 

That creates a fundamental trade-off: 

The smaller the pixels become, the greater the potential spatial resolution, but the harder it becomes to generate and control effective neural stimulation. 

PRIMA Retinal Implant Clinical Evidence: 38 Patients 

The most important evidence comes from the prospective clinical study published in the New England Journal of Medicine in October 2025. 

A total of 38 participants received a PRIMA implant. 

At the 12-month assessment: 

• 32 patients were evaluated. 
• 26 of 32 (81%) achieved clinically meaningful visual-acuity improvement. 
• The 95% confidence interval was 64% to 93%. 
• Statistical significance was P<0.001. 
• After multiple imputation for missing participants, researchers estimated that 80% of the entire cohort would have achieved clinically meaningful improvement. 
• The confidence interval for that estimate was 66% to 94%. 

Clinical Outcomes: Two Numbers, Two Different Results 

At 12 months, the PRIMA retinal implant showed two notable outcomes among the 32 patients assessed. 

The distinction matters. 

81% measures a predefined improvement in visual acuity, while 84% reflects functional reading ability using prosthetic vision. They measure different aspects of PRIMA’s performance and should not be treated as the same outcome. 

What Did Patients Actually See? 

This is where the PRIMA story becomes more meaningful than a conventional visual-acuity result. 

At 12 months: 

27 of 32 patients, or 84%, could read letters, numbers and words using prosthetic vision at home. 

The NEJM study also reported that 69% of participants, or 22 of 32, could read letters, numbers and words using prosthetic vision during testing. 

UCL’s clinical reporting similarly highlighted the ability of participants to read letters, numbers and words, with participants reading an average of approximately five lines on a visual-acuity chart. 

That is an important distinction. 

The PRIMA retinal implant is not simply producing a perception of light. 

It is producing enough structured information for many participants to interpret letters, numbers and words. 

PRIMA Works, But Vision Is Still Limited 

Patients improved by an average of 5 vision-chart lines, with one gaining 12 lines. With zoom and higher contrast, some reached vision equivalent to 20/42. 

However, PRIMA does not restore natural sight. 

Current vision is limited by 100-µm pixels, contrast and image complexity, while facial recognition remains challenging. The next-generation chip aims for 20-µm pixels and 10,000 pixels, potentially enabling much sharper vision. 

The Resolution Bottleneck 

The 100-µm pixel size is one of the most important technical specifications of the PRIMA retinal implant. 

It is also one of its biggest limitations. 

The retinal implant effectively samples the visual scene at a relatively coarse spatial resolution. Smaller pixels could theoretically produce finer visual information. 

But there is a catch. 

The implant must create an electrical field strong and localized enough to stimulate the appropriate retinal neurons. 

As pixel dimensions decrease, maintaining effective stimulation becomes increasingly difficult. 

So the engineering problem becomes: 

This is why the next generation of retinal prostheses cannot simply be described as “more pixels.” 

The real objective is: 

More useful information per pixel. 

PRIMA Retinal Implant Safety Data 

A breakthrough implant still has to justify the risks of surgery and implantation. 

In the pivotal study: 

26 serious adverse events occurred in 19 participants. 

This is important because the PRIMA retinal implant is designed to restore central vision without sacrificing the patient’s remaining natural peripheral vision. 

From 5 Patients to 38: PRIMA’s Clinical Development 

PRIMA’s development also illustrates how experimental neurotechnology moves toward clinical validation. 

The significance of the 2025 NEJM publication is that PRIMA moved from being primarily an experimental technology story into one supported by prospective human clinical evidence. 

2026: PRIMA Moves From Trial to Commercial Product 

The biggest development since the clinical publication is regulatory and commercial. 

On 22 July 2026, Science Corporation announced that PRIMA had received CE marking for form-vision restoration in patients with geographic atrophy caused by AMD. 

The company said reimbursement applications and clinical-site activations were underway across Europe, with the first commercial implantation expected in Germany. 

The CE marking makes PRIMA commercially available across 30 European countries, according to industry reporting. 

Commercial Transition 

The move from clinical trial to commercial product represents an important transition for the PRIMA retinal implant. 

The technology is no longer being evaluated solely as an experimental retinal prosthesis. It is entering a regulated commercial environment where factors such as reimbursement, surgical infrastructure, patient selection, training and long-term follow-up become increasingly important. 

The Economics Could Become the Next Bottleneck 

The clinical breakthrough does not automatically mean mass adoption. 

PRIMA requires: 

• specialized retinal surgery; 
• an implanted device; 
• external hardware; 
• patient training; 
• specialist follow-up; 
• rehabilitation; 
• manufacturing infrastructure. 

Science Corporation has already invested heavily in bringing the technology toward commercialization. 

In March 2026, the company announced a $230 million Series C financing round, bringing reported total capital raised to approximately $490 million. 

Capital Trajectory 

The investment reflects the cost of turning a highly specialized neurotechnology into a regulated medical product. 

The IP Battle Behind the Bionic Eye 

The competitive moat surrounding the PRIMA retinal implant goes far beyond its 2-mm retinal chip. 

Its technology spans: 

• photovoltaic pixels; 
• optical stimulation; 
• signal processing; 
• AI; 
• software. 

Patent protection is already part of that journey. 

Key filings include US20240058607A1, while EP4312882B1 was granted in Europe in February 2026. 

The bigger opportunity lies ahead. 

As PRIMA moves toward higher-resolution vision, the next IP battle could be fought as much in software and AI as in the implant itself. 

PRIMA Is Also Becoming an AI Problem 

The current device already relies on computational processing, but future systems could go much further. 

Imagine a camera capturing a complex scene while an algorithm decides what information the implant should preserve. 

With limited resolution, the implant cannot transmit everything. It has to prioritize: 

• a letter; 
• an edge; 
• a face; 
• a doorway; 
• a road sign; 
• an obstacle. 

Future artificial-vision systems could therefore work like task-optimized visual compression, with AI identifying and encoding the information most useful to the patient rather than reproducing the entire visual field. 

Research is already exploring machine learning to improve facial representation within PRIMA’s spatial and contrast limitations. 

This creates an important future direction for the PRIMA retinal implant: improving vision may depend not only on increasing the number of pixels, but also on making computational decisions about which visual information matters most. 

What Comes Next for the PRIMA Retinal Implant? 

Science Corporation is also pursuing broader applications of the PRIMA platform, including retinal diseases such as Stargardt disease and retinitis pigmentosa. 

These applications remain investigational. 

But if the underlying architecture can be adapted across different forms of photoreceptor degeneration, the addressable population could expand significantly. 

The technology roadmap therefore looks something like this: 

The Bigger Picture: Beyond the PRIMA Retinal Implant 

The significance of the PRIMA retinal implant goes beyond AMD. 

It shows that medicine may not always need to repair damaged biology to restore function. It can sometimes build an alternative pathway. 

By connecting a photovoltaic interface to surviving retinal circuitry, PRIMA shifts the question from: 

“How do we regenerate the retina?” 

to: 

“How do we communicate with what remains?” 

PRIMA Retinal Implant by the Numbers 

Sources: NEJM, Science Corporation and 2026 industry reporting, mentioned at the end. 

Conclusion: The Beginning of an Artificial Vision Era 

The PRIMA retinal implant does not restore natural eyesight. 

Instead, it demonstrates that electronics can bypass damaged photoreceptors and restore useful vision. 

Its next challenge is no longer simply proving that the technology works, but determining how far engineered vision can be improved. 

That future will be shaped by neuroscience, AI, semiconductor engineering and IP and by one defining question: 

How close can artificial vision get to the real thing? 

Sources

• NEJM — PRIMA Clinical Study 
• Science Corporation — CE Mark Announcement 
• Science Corporation — PRIMA Technology 
• ClinicalTrials.gov — PRIMAvera Study 
• Nature Communications — PRIMA Retinal Prosthesis 
• UCL — PRIMA Clinical Results 
• ClinicalTrials.gov — PRIMA Feasibility Study 
• European Patent EP4312882B1 
• U.S. Patent Publication US20240058607A1 
• Touch Ophthalmology — PRIMA CE Marking 
• STAT — European Launch and U.S. Pathway 
• TechCrunch — $230M Financing